Chemistry Reference
In-Depth Information
[30] Yaar M, Zhai S, Pilch FP, Doyle MS, Eisenhauer BP, Fine ER, et al., Binding of beta-amyloid to the p75 neurotrophin
receptor induces apoptosis - A possible mechanism for Alzheimer's disease. J. Clin. Invest. 1997; 100: 2333-2340.
[31] Estus S, Tucker MH, van Rooyen C, Wright S, Brigham FE, Wogulis M. et al., Aggregated amyloid-beta protein induces
cortical neuronal apoptosis and concomitant "apoptotic" pattern of gene induction, J. Neurosci., 1997; 17: 7736-7745.
[32] Álvarez G, Muñoz Montaño JR, Satrustegui J, Ávila J, Bogónez E, Díaz-Nido J, Regulation of tau phosphorylation and
protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease.
Bipolar Disord. 2002; 4(3): 153-165
[33] Hardy JA, Higgins GA, Alzheimer's disease: The amyloid cascade hypothesis, Science 1992; 256: 184-185.
[34] Embin, N, Rylatt DB, Cohen P. Glycogen synthase glycogen synthase kinase 3_beta: structural basis for phosphatekinase-
3 from rabbit skeletal muscle. Seperation from cyclic- primed substrate specificity and autoinhibition. Eur. J. Biochem.
1980; 107: 519-527.
[35] Goedert M, Jakes R, Crowther RA, Cohen P, Vanmechelen E, Vandermeeren M, Cras P. Epitope mapping of monoclonal
antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein.
Biochem. J., 1994; 301: 871-877.
[36] Jicha GA, Lane E, Vincent I, Otvos L Jr., Hoffmann R, Davies PA. A conformation- and phosphorylation-dependent
antibody recognizing the paired helical filaments of Alzheimer's disease. J. Neurochem. 1997; 69(5): 2087-2095.
[37] Daly NL, Hoffmann R, Otvos LJr, Craik DJ. Role of phosphorylation in the conformation of tau peptides implicated in
Alzheimer's disease, Biochemistry, 2000; 39(30): 9039-9046.
[38] Avila J, Hernández F. GSK-3 inhibitors for Alzheimer's disease. Expert Rev. Neurother. 2007; 7(11): 1527-1533.
[39] Martinez A. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs, Med. Res. Rev.
2008; 28(5): 773-796.
[40] Hopper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J. Neurochem. 2008; 104(6): 1433-1439.
[41] Woodgett J.R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. Embo J., 1990; 9(8): 2431-2438.
[42] Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, Gallo JM, Hanger D, Mulot S, Marquardt B, Stabel S.
Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in
transfected mammalian cells. Curr. Biol., 1994; 4: 1077-1086.
[43] Hong M, Chen DC, Klein PS, Lee VM, Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3.
J. Biol. Chem. 1997; 272: 25326-25332.
[44] Muñoz-Montaño JR, Moreno FJ, Avila J, Diaz-Nido, J, Lithium inhibits Alzheimer's disease-like tau protein
phosphorylation in neurons. FEBS Lett. 1997; 411: 183-188.
[45] Spittaels K, Van den Haute C, Van Dorpe J, Geerts H, Mercken M, Bruynseels K, Lasrado R, Vandezande K, Laenen I,
Boon T, Van Lint J, Vandenheede J, Moechars D, Loos R, Van Leuven F, J. Biol. Chem. 2000; 275: 41340-41349.
[46] Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau
hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 2001; 20: 27-39.
[47]
Engel T, Hernandez F, Avila J, Lucas JJ. Full reversal of Alzheimer's disease-like phenotype in a mouse model with
conditional overexpression of glycogen synthase kinase-3. J. Neurosci., 2006; 26: 5083-5090.
[48]
Meijer L., Flajolet M, Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3, Trends Pharmacol. Sci.
2004; 25: 471-480.
[49]
Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides,
Nature. 2003; 423: 435-439.
[50]
Takashima A, Murayama M, Murayama O, Kohno T, Honda T, Yasutake K, Nihonmatsu N, Mercken M, Yamaguchi H,
Sugihara S, Wolozin B, Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc. Natl. Acad.
Sci. USA 1998; 95: 9637-9641.
[51]
Zhang Z, Hartmann H, Do VM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Sommer B, van de Wetering M,
Clevers H, Saftig P, De Strooper B, He X, Yankner BA. Destabilization of beta-catenin by mutations in presenilin-1
potentiates neuronal apoptosis. Nature 1998; 395: 698 -702.
[52]
Perez M, Hernandez F, Lim F, Diaz-Nido J, Avila J, Chronic lithium treatment decreases mutant tau protein aggregation in
a transgenic mouse model. J. Alzheimers Dis. 2003; 5: 301-308.
[53]
Engel T, Goni-Oliver P, Lucas JJ, Avila J, Hernandez F, Chronic lithium administration to FTDP-17 tau and GSK-3beta
overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed
neurofibrillary tangles do not revert. J. Neurochem. 2006; 99: 1445-1455.
[54]
Le Corre S, Klafki HW, Plesnila N, Hubinger G, Obermeier A, Sahagun H, Monse B, Seneci P, Lewis J, Eriksen J, Zehr
C, Yue M, McGowan E, Dickson DW, Hutton M, Roder HM. An inhibitor of tau hyperphosphorylation prevents severe
motor impairments in tau transgenic mice, Proc. Natl. Acad. Sci. USA, 2006: 103, 9673-9678.
